MODERATOR(S)
Alexander Louie, MD, PhD, MSc, FRCPC - Sunnybrook Health Sciences Centre
session DESCRIPTION
This session will discuss current evidence and best practices for SBRT in the management of lung cancer. For early stage NSCLC, SBRT is well-established as the gold standard for medically inoperable patients, where it is exceptionally well-tolerated. Data and technical considerations of challenging cases, including ultra-central location, co-existing interstitial lung disease and repeat SBRT will be reviewed. In locally advanced NSCLC, recent data using neoadjuvant chemo/immunotherapy has reinvigorated discussion on standards and definitions related to operability and resectability. A less appreciated development is the newer and evolving application of SBRT in this space. Finally, in the context of oligometastatic and oligoprogressive lung cancer, nuances on the integration of SBRT with novel systemic therapies, commonly delivered dose fractionations, and the treatment scheduling of multiple targets will be reviewed.
learning objectives
- Review strategies to optimize the therapeutic ratio in challenging cases of SBRT for early stage lung cancer.
- Discuss the potential role of SBRT for locally advanced lung cancer.
- Recognize the growing utility of SBRT in metastatic, oligometastatic and oligoprogressive lung cancer.
Credits
| AMA PRA Category 1 Credits: | 1.00 |
Presentations
-
03:00pm - 03:02pm ETSpeaker: Alexander Louie, MD, PhD, MSc, FRCPC - Sunnybrook Health Sciences Centre, Toronto
-
03:02pm - 03:17pm ETSpeaker: Florence Keane, MD - Massachusetts General Hospital/ Harvard Medical School, Boston
-
03:17pm - 03:32pm ETSpeaker: Arya Amini, MD - City of Hope National Medical Center, Duarte
-
03:32pm - 03:47pm ETSpeaker: Houda Bahig, MD, PhD - Centre Hospitalier de l'Universite de Montreal, Montreal
-
03:47pm - 04:00pm ETSpeaker: Alexander Louie, MD, PhD, MSc, FRCPC - Sunnybrook Health Sciences Centre, Toronto